spacer
home > ebr > spring 2019 > bridging the gap
PUBLICATIONS
European Biopharmaceutical Review

Bridging the Gap

Regenerative medicine (the art of repairing or replacing damaged tissues and organs through cellular engineering) has seen remarkable advances in the past decade. Positive clinical trial results, particularly in cancer immunotherapy, have prompted a surge in the number of cell-based therapies progressing toward commercialisation. Apheresis and cell collection centres must quickly adapt to handle the increased demand for cell therapy starting materials. Concerns over upholding quality oversight, particularly for Good Manufacturing Practice (GMP)-qualified starting materials, should also be addressed.

Apheresis collection centres interact closely with both donors and the pharmaceutical companies developing cellular therapies and are, therefore, in an ideal position to devise solutions to these challenges. This article will focus on how apheresis facilities aim to adapt collection centre infrastructure to support higher demand while streamlining downstream processing and ensuring quality oversight. The authors will examine specific quality control challenges posed by cryopreserved GMP products and the related need to adapt and standardise cold chain protocols. Bridging the gap from donor collection to successful therapeutic relies on the ability to collect high-quality starting material and assure that the finest quality and efficacy of the final cell-based product can be achieved.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dominic Clarke PhD has over 15 years’ experience developing enabling solutions for cell therapy and bioprocessing applications. Dominic is the Global Head of Cell Therapy at HemaCare, where he is actively engaged with industry experts to ensure the highest quality materials are delivered. Previously, he held roles as the Global Product Manager for Charter Medical’s cell therapy and bioprocessing disposables portfolio, focussed on creating flexible closed-system solutions for early- and late-stage production, and as the Director of Research and Development at BioLife Solutions, developing novel biopreservation media and methods to support extended stability of cells and tissues.

Brad N Taylor PhD is the Senior Product Manager at HemaCare. Brad has over 13 years’ experience in the biotechnology industry, addressing multiple aspects of drug discovery and preclinical development. Previously, he held roles as Application Scientist and Product Manager in the in vivo imaging division of PerkinElmer, where he worked to bring innovative solutions to market to assist the research community in expediting and streamlining the process of preclinical drug discovery for cancer and other clinical applications in animal models of disease.
spacer
Dominic Clarke PhD
spacer
spacer
spacer
Brad N Taylor PhD
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Introducing Signant Health [Formerly CRF Bracket] and the Industry’s Most Comprehensive Patient-Centric Suite for Clinical Research

Philadelphia and London – June 10, 2019: CRF Bracket, formed by the 2018 merger of CRF Health and Bracket, today launched as Signant Health (signanthealth.com). Uniting eCOA, eConsent, Patient Engagement, IRT, Clinical Supplies and Endpoint Quality into the industry’s most comprehensive patient-centric suite, Signant makes it easier to participate in – and sites and study teams to run – clinical trials. This intense focus on the patient experience, deep therapeutic area expertise and global operational scale enable sponsors and CROs to extend the reach of drug development, expand patient opportunities and improve data quality.
More info >>

White Papers

Sourcing Commercial Drugs for Clinical Trials: US vs. EU Understanding the Differences

Myoderm

Sourcing commercial drugs for clinical trials is a dynamic process. There are many factors to consider: single source or regional sourcing, strategy, price, supply availability, lead times, and documentation are just a few. In the past, there were fewer clinical trials that required commercial drug sourcing, so demand was not as high. Today, the demand for commercial drugs in clinical trials has greatly increased and, as a result, inventory is tighter, orders are monitored more closely by manufacturers, and lead times have increased. This report highlights the key differences in sourcing from the US and EU.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement